Reflections on the importance of factor VIII and Von Willebrand factor pharmacokinetics in the safety and efficacy of current Von Willebrand factor concentrates
- 2026, Volume 3 - Number 2
- Published: July 24, 2024
Reflections on the importance of factor VIII and Von Willebrand factor pharmacokinetics in the safety and efficacy of current Von Willebrand factor concentrates
Ramon Salvado 1, Ramiro J. Núñez-Vázquez 2, Manuel Rodríguez-López 3
1 Serviço de Imuno-Hemoterapia, Centro de Referência de Coagulopatias Congénitas, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2 Unidad de Trombosis y Hemostasia, Servicio de Hematologia y Hemoterapia, Hospital Universitario Virgen del Rocío, Sevilla, España; 3 Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España
Ramon Salvado, Ramiro J. Núñez-Vázquez, Manuel Rodríguez-López
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Manuel Rodríguez-López, Email not available
Summary
Prophylaxis in Von Willebrand disease is addressed, focusing on the composition and efficacy of Von Willebrand factor concentrates. Three products with different characteristics in terms of their origin and composition (Veyvondi®, Wilate®, and Wilfact®) are compared, highlighting their differences in weekly consumption, infusions and thrombotic events. The results indicate that Wilate® has a lower weekly intake and comparable efficacy in reducing bleeding. The accumulation of factor VIII and its relationship with thrombotic risk are discussed, underlining the importance of precise dosing to maximize efficacy and minimize safety and economic risks.
Keywords: Von Willebrand disease. Prophylaxis. FVIII/VWF ratio. Randomized controlled trials. Thrombin generation.
